Abstract:Proteolysis targeting chimeras (PROTACs) technology has emerged as a novel therapeutic paradigm in recent years. PROTACs are heterobifunctional molecules that degrade target proteins by hijacking the ubiquitin-proteasome system. Currently, about 20-25% of all protein targets are being studied, and most works focus on their enzymatic functions. Unlike small molecules, PROTACs inhibit the whole biological function of the target protein by binding to the target protein and inducing subsequent proteasomal degradation. PROTACs compensate for limitations that transcription factors, nuclear proteins, and other scaffolding proteins are difficult to handle with traditional small-molecule inhibitors. Currently, PROTACs have successfully degraded diverse proteins, such as BTK, BRD4, AR, ER, STAT3, IRAK4, tau, etc. And ARV-110 and ARV-471 exhibited excellent efficacy in clinical II trials. However, what targets are appropriate for PROTAC technology to achieve better benefits than small-molecule inhibitors are not fully understood. And how to rationally design an efficient PROTACs and optimize it to be orally effective poses big challenges for researchers. In this review, we summarize the features of PROTAC technology, analyze the detail of general principles for designing efficient PROTACs, and discuss the typical application of PROTACs targeting different protein categories. In addition, we also introduce the progress of relevant clinical trial results of representative PROTACs and assess the challenges and limitations that PROTACs may face. Collectively, our studies provide references for further application of PROTACs.

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs

Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Recent Advances in PROTACs for Drug Targeted Protein Research

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

An overview of PROTACs: a promising drug discovery paradigm

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs